Study for effectiveness of Unani drugs in white patches (vitiligo)

A Clinical Study to Evaluate the Efficacy and Safety of Habb-i Hindi (O) and Habb-i Baras (L) in the Management of Baras (Vitiligo)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/12/010998

Enrollment

Registered

2017-12-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo Health Condition 2: L80- Vitiligo

Interventions

Intervention1: Group (A) Unani Drugs Habbi Hindi (Oral) and Habbi Baras (Local): Habbi Hindi: Patients will be advised to take 6 pills (500mg each) orally twice daily an hour after meals. Habbi Baras:

Eligibility

Inclusion criteria

Inclusion criteria: Patients of any sex in the age group between 18 and 40 Years Patients with NonSegmental Vitiligo (NSV), disease chronicity from 6 months to 2 years Vitiligo involving more than 2% Body Surface Area (BSA) Patients with less than 5 New Lesions in the last month Patients with less than 15 lesions in the last 3 months Patients who have not received systemic treatment within 4 weeks prior to study entry Patients who have not received topical treatment within 2 weeks prior to study entry

Exclusion criteria

Exclusion criteria: Patients aged less than 18 years or more than 40 years Pregnant or Lactating Women Segmental Vitiligo (SV), liptip, or universal Vitiligo, or Vitiligo with leucotrichia History of Photosensitivity/Photoexaggerated Dermatoses and Connective Tissue Diseases Significant Pulmonary/Cardiovascular/Hepatorenal Dysfunction 6. Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies (Cutaneous or Internal) Patient not willing to attend treatment schedule regularly Patients not having a suitable facility for sun exposure

Design outcomes

Primary

Measure	Time frame
To compare relative efficacy of Unani drugs Habbi Hindi(o) and Habbi Baras(l) and Cmparator group PUVAsol and topical mometasone nonsegmental vitiligo by using VASI and VIDA Score To evaluate safety of Unani drugs Habbi Hindi(o) and Habbi Baras and comparator PUVAsol and topical mometasone Non segmental vitiligoTimepoint: At baseline 4wk 8wk 12wk and 16wk	—

Secondary

Measure	Time frame
To compare the improvement in quality of life in patients with vitiligo assessed by PGA on VAS and IGATimepoint: At baseline 4wk 8wk 12wk and 16wk	—

Countries

India

Contacts

Public ContactDr Mohammad Nawab

Central Research Institute of Unani Medicine, Hyderabad

ccrumhqrsnd58@gmail.com8700027178

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026